EUCTR2005-005885-36-IT进行中（未招募）不适用
Dose finding study of Liposomal Doxorubicin Myocet in combination with Capecitabine Xeloda in the treatment of metastatic breast cancer patients - ND
AZIENDA USL DI FORLI0 个研究点目标入组 30 人开始时间: 2006年3月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically or cytologically proven breast carcinoma with metastatic or locally advanced disease. Any estrogen or progesterone receptor status. Prior chemotherapy for metastatic disease. At least a 4-week interval between the last dose of chemotherapy and study entry. Recovery from all prior treatment-related toxicities to CTC grade 1 except alopecia .
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Unstable angina, myocardial infarction, or congestive heart failure in the last six months. Serious active infection at the time of study entry or other serious underlying medical conditions which would impair the ability of the patient to receive protocol treatment. Patients who have never received prior chemotherapy for metastatic breast cancer. Previous chemotherapy with total dose of doxorubicin 300 mg/m2 or epirubicin 450 mg/m2. Need for concomitant radiotherapy
研究者
相似试验
进行中（未招募）
1 期
Phase II study evaluating the combination of liposomal doxorubicin pluscyclophosphamide with trastuzumab followed by docetaxel plustrastuzumab as therapy to be performed before surgery (neoadjuvantchemotherapy) for patients with breast cancer more than 2 cm in size and possible involvement of the lymph nodes adjacent and with the receptor HER2 positive.MedDRA version: 14.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864ocal advanced breast cancer resectable, neoadjuvant settingEUCTR2013-002684-25-ITS.I.C.O.G. ONLUS41
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
进行中（未招募）
1 期
A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old with metastatic breast cancer. - DOGMESBreast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-002736-28-FRARCAGY-GINECO60
已完成
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD) + Carboplatin (CBDCA) as Treatment in Relapsed, Plutinum-sensitive Ovarian CancerOvarian cancerJPRN-UMIN000003944Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology85
进行中（未招募）
不适用
Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy - AROBASEBreast Cancer Patients with Brain MetastasesMedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006790-81-FRAPREC50